XJ
Xu, J.
5 papers · 45 citations · 2023–2025
Publications
5
Citations
45
Years
3
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial
|
2025 | Article | 2 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 38 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 0 |
|
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
|
2023 | Meeting Abstract | 0 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
|
2023 | Meeting Abstract | 5 |